Sui's Bitcoin finance system, Hashi, is set to launch on mainnet later this month with over $500 million in capital commitments from more than 20 launch partners, including Anchorage Digital as a Day 1 partner. Hashi allows users to deposit Bitcoin which remains on the Bitcoin network while minting a token called hBTC on Sui for use in third-party apps. The system uses a secure 2-of-2 multisig for deposits and redemptions, and legal advice suggests these steps may not be taxable events in the US. Anchorage offers institutional clients access via tri-party collateral or self-custody, with plans to provide stablecoin liquidity. The exact launch date and Fluid's confirmed role in lending remain unclear, with phased access depending on partner integration progress. The key upcoming event is Hashi's mainnet launch and partner activation timeline.
Sui's Bitcoin finance system Hashi is launching soon. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 23, 2026 16:51 WIB: 31 of 50 major cryptocurrencies rose today. Kusama (KSM) gained 2.76% to Rp73.118 with 100% buy orders. Compound (COMP) fell 2.72% to Rp438.382 with 74% sell orders. The Graph (GRT) rose 2.41% to Rp437 with 96% buy orders.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
